US1.15

GSK to buy US cancer biotech IDRx for up to US$1.15 billion

January 13, 2025

[ad_1] GSK agreed to buy US biotech IDRx for as much as US$1.15 billion to gain new cancer medicines. The UK drugmaker will pay US$1 billion upfront for IDRx, whose lead...